Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $114.61 USD
Change Today +0.31 / 0.27%
Volume 2.9M
As of 8:04 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

amerisourcebergen corp (ABC) Snapshot

Open
$115.12
Previous Close
$114.30
Day High
$115.32
Day Low
$113.83
52 Week High
04/30/15 - $120.68
52 Week Low
05/5/14 - $63.88
Market Cap
25.2B
Average Volume 10 Days
2.0M
EPS TTM
$2.16
Shares Outstanding
219.6M
EX-Date
02/12/15
P/E TM
53.0x
Dividend
$1.16
Dividend Yield
0.92%
Current Stock Chart for AMERISOURCEBERGEN CORP (ABC)

amerisourcebergen corp (ABC) Details

AmerisourceBergen Corporation sources and distributes pharmaceutical products to healthcare providers, pharmaceutical and biotech manufacturers, and specialty drug patients in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; scalable automated pharmacy dispensing equipment; medication and supply dispensing cabinets; and packaging solutions to institutional and retail healthcare providers. In addition, this segment provides pharmaceutical distribution and other services primarily to physician practices in various disease states, such as oncology, as well as to other healthcare providers, including dialysis clinics; distributes plasma and other blood products, injectible pharmaceuticals, and vaccines; and third party logistics and outcomes research, and other services for biotechnology and other pharmaceutical manufacturers. The company’s Other segment provides commercialization support services, including reimbursement support programs, outcomes research, contract field staffing, patient assistance and co-pay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical and biotechnology manufacturers; and specialty transportation and logistics services for the biopharmaceutical industry. AmerisourceBergen Corporation markets its products and services through independent sales forces and marketing organizations. The company was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.

16,000 Employees
Last Reported Date: 04/30/15
Founded in 1985

amerisourcebergen corp (ABC) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.2M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $632.7K
Executive Vice President of Retail Strategy a...
Total Annual Compensation: $626.5K
Executive Vice President and President of Ame...
Total Annual Compensation: $515.0K
Executive Vice President and General Counsel
Total Annual Compensation: $584.1K
Compensation as of Fiscal Year 2014.

amerisourcebergen corp (ABC) Key Developments

AmerisourceBergen Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2015; Revised Earnings Guidance for the Year of 2015

AmerisourceBergen Corporation reported unaudited consolidated earnings results for the second quarter and six months ended March 31, 2015. For the quarter, the company reported revenue of $32,669,267,000 compared to $28,455,903,000 a year ago. Operating loss was $364,249,000 compared to operating income of $301,128,000 a year ago. Loss before income taxes was $398,600,000 compared to income before income taxes of $285,437,000 a year ago. Net loss was $513,390,000 or $2.33 per diluted share compared to net income of $180,077,000 or $0.76 per diluted share a year ago. Non-GAAP operating income was $552,725,000 compared to $416,562,000 a year ago. Non-GAAP income before income taxes was $520,806,000 compared to $153,133,000 a year ago. Non-GAAP net income was $334,797,000 or $1.45 per diluted share compared to $247,738,000 or $1.06 per diluted share a year ago. The company generated $700 million in operating cash flow. Free cash flow was $690 million. For the six months, the company reported revenue of $66,257,869,000 compared to $57,632,265,000 a year ago. Operating loss was $452,646,000 compared to operating income of $460,744,000 a year ago. Loss before income taxes was $505,653,000 compared to income before income taxes of $426,818,000 a year ago. Net loss was $713,337,000 or $3.24 per diluted share compared to net income of $221,462,000 or $0.94 per diluted share a year ago. Loss from continuing operations was $713,337,000 or $3.24 per diluted share compared to income from continuing operations of $229,008,000 or $0.97 per diluted share a year ago. Non-GAAP operating income was $988,292,000 compared to $739,294,000 a year ago. Non-GAAP income before income taxes was $940,155,000 compared to $269,451,000 a year ago. Non-GAAP net income was $595,212,000 or $2.59 per diluted share compared to $435,917,000 or $1.86 per diluted share a year ago. Net cash provided by operating activities was $1,638,684,000 compared to $112,653,000 a year ago. Capital expenditures were $105,201,000 compared to $125,392,000 a year ago. For the year 2015, the company expects adjusted diluted earnings per share from continuing operations in the range of $4.85 to $4.95, a 22% to 25% increase over fiscal 2014, and an increase over prior guidance of $4.53 to $4.63; revenue growth in the range of 12% to 13%; adjusted operating income growth in the 19% to 21% range; adjusted operating margin increase of 8 to 10 basis points; free cash flow generation in the range of $2.0 billion to $2.3 billion; and capital expenditures in the $250 million range. The company expects tax rate to be between 36% and 37%.

NovaBay Pharmaceuticals, Inc. Signs Distribution Agreement with AmerisourceBergen Corporation for Avenova

NovaBay Pharmaceuticals, Inc. announced that it has signed a nationwide distribution agreement with AmerisourceBergen Corporation. Under the agreement, AmerisourceBergen will carry and distribute NovaBays Avenova a prescription lid and lash hygiene product for the management of debilitating eye conditions such as blepharitis, Meibomian gland dysfunction and associated dry eye, to independent and retail chain pharmacies across the U.S.

AmerisourceBergen Corporation, Q2 2015 Earnings Call, Apr 30, 2015

AmerisourceBergen Corporation, Q2 2015 Earnings Call, Apr 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABC:US $114.61 USD +0.31

ABC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $69.43 USD +0.69
Cardinal Health Inc $85.55 USD +1.21
Henry Schein Inc $138.84 USD +1.74
McKesson Corp $224.94 USD +1.54
Tractor Supply Co $87.16 USD +1.10
View Industry Companies
 

Industry Analysis

ABC

Industry Average

Valuation ABC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book 13.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMERISOURCEBERGEN CORP, please visit www.amerisourcebergen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.